Skip to main content

Table 1 Patient characteristics

From: 18 F-FDG PET-CT during chemo-radiotherapy in patients with non-small cell lung cancer: the early metabolic response correlates with the delivered radiation dose

Patient

Sex

Age

Pathology

cTNM

Metabolic response (EORTC) on during-RT PET-CT

Metabolic response (EORTC) on post-RT PET-CT

Surgery

pTNM

1

F

43

Adenocarcinoma

T3N2M0

SMD

PMR

yes

T3N1M0

2

M

53

Adenocarcinoma

T2N1M0

PMR

PMR

yes

T2N0M0

3

F

54

Adenocarcinoma

T4N0M0

PMR

PMR

yes

T1N0M0

4

M

59

SCC

T2N2M0

PMR

CMR

yes

T1N1M0

5

F

60

Adenocarcinoma

T4N2M0

PMR

PMR

yes

T1N0M0

6

M

60

SCC

T3N2M0

PMR

CMR

yes

T1N0M0

7

M

64

Large cell carcinoma

T2N1M0

PMR

CMR

yes

T0N2M0

8

M

65

SCC

T4N1M0

PMR

PMR

no

 

9

F

77

Adenocarcinoma

T4N2M0

PMR

PMR

no

 

10

M

78

SCC

T3N2M0

PMR

CMR

yes

T1N0M0

11

M

62

Adenocarcinoma

T4N2M0

SMD

PMR

no

 

12

M

70

Adenocarcinoma

T4N3M0

PMR

PMR

no

 

13

M

73

SCC

T3N2M0

PMR

PMR

no

 

14

M

55

Adenocarcinoma

T4N0M0

SMD

no

 

15

M

58

Adenocarcinoma

T2N2M0

No scan

CMR

yes

T3N2M0

16

M

62

Large cell carcinoma

T4N2M0

PMR

No scan

yes

T3N0M0

17

M

63

Adenocarcinoma

T4N2M0

No scan

CMR

yes

T0N0M0

18

M

69

Adenocarcinoma

T3N2M0

No scan

CMR

yes

T0N0M0

19

M

71

SCC

T2N1M0

No scan

PMR

no

 

20

M

62

SCC

T4N2M0

No scan

PMR

no

 

21

M

69

SCC

T4N2M0

SMD

no

 

22

M

68

SCC

T2N0M0

PMR

no

 

23

M

74

Adenocarcinoma

T4N3M0

No scan

PMR

no

 

24

M

63

Adenocarcinoma

T3N2M0

No scan

SMD

no

 

25

M

65

SCC

T3N0M0

No scan

CMR

yes

T1N0M0

  1. SCC, squamous cell carcinoma; CMR, complete metabolic response; PMR, partial metabolic response; SMD, stable metabolic disease. †Patient died within 70 days after radiotherapy.